Pacira Pharmaceuticals (PCRX) saw its stock price plummet by 13.37% during intraday trading on Friday, as investors reacted to the company's preliminary FY25 revenue results.
The sharp decline followed the release of the preliminary financial results, which likely fell short of market expectations. The healthcare sector was already under pressure, with health care stocks dipping by 0.5% on Friday, adding to the downward momentum for PCRX.